← Leaderboards
Christopher J. Ward
Mayo Clinic
$5,757,248
Attributed
$6,230,109
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $489.1K · FY2005–24$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,230,109 · 5
By mechanism
R01$4,481,216 · 3
RC1$945,723 · 1
P30$803,170 · 1
Top collaborators
- Marie C Hogan2 shared
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsGenesMutationPkd2 ProteinPolycystic Kidney Disease 1 ProteinMessenger RnaKidneyPkd1 GeneSignal TransductionDesignComplexResearch PersonnelCystAffectUrineUrinaryVesicleAutosomal Dominant Polycystic KidneyPathway InteractionsCellsIntronsPathogenesisGenomeInherited
Grant awards (21)
Human-specific Abnormal Alternative Splicing of the Wild-type PKD1 Gene Induces Premature Termination of Polycystin-1$323,136
R01 · FY2024 · DK · contact PI
Human-specific Abnormal Alternative Splicing of the Wild-type PKD1 Gene Induces Premature Termination of Polycystin-1$336,600
R01 · FY2023 · DK · contact PI
Human-specific Abnormal Alternative Splicing of the Wild-type PKD1 Gene Induces Premature Termination of Polycystin-1$336,600
R01 · FY2022 · DK · contact PI
Human-specific Abnormal Alternative Splicing of the Wild-type PKD1 Gene Induces Premature Termination of Polycystin-1$336,600
R01 · FY2021 · DK · contact PI
Human-specific Abnormal Alternative Splicing of the Wild-type PKD1 Gene Induces Premature Termination of Polycystin-1$336,600
R01 · FY2020 · DK · contact PI
Biomedical Research Core 1: Gene Targeting Core$160,634
P30 · FY2019 · DK · contact PI
Biomedical Research Core 1: Gene Targeting Core$160,634
P30 · FY2018 · DK · contact PI
Biomedical Research Core 1: Gene Targeting Core$160,634
P30 · FY2017 · DK · contact PI
Biomedical Research Core 1: Gene Targeting Core$160,634
P30 · FY2016 · DK · contact PI
Functional analysis of PKD proteins in urinary exosomes$328,425
R01 · FY2015 · DK · contact PI
Biomedical Research Core 1: Gene Targeting Core$160,634
P30 · FY2015 · DK · contact PI
Functional analysis of PKD proteins in urinary exosomes$328,425
R01 · FY2014 · DK · contact PI
Functional analysis of PKD proteins in urinary exosomes$342,998
R01 · FY2012 · DK · contact PI
Functional analysis of PKD proteins in urinary exosomes$394,250
R01 · FY2011 · DK · contact PI
Analysis of the proteome of PKD-ELVs in polycystic kidney disease and controls$473,836
RC1 · FY2010 · DK · contact PI
Analysis of the proteome of PKD-ELVs in polycystic kidney disease and controls$471,887
RC1 · FY2009 · DK · contact PI
Analysis of ARPKD by Targeted Manipulation of Pkhd1$271,378
R01 · FY2008 · DK · contact PI
Analysis of ARPKD by Targeted Manipulation of Pkhd1$276,917
R01 · FY2007 · DK · contact PI
Analysis of ARPKD by Targeted Manipulation of Pkhd1$285,187
R01 · FY2006 · DK · contact PI
Analysis of ARPKD by Targeted Manipulation of Pkhd1$292,050
R01 · FY2005 · DK
Analysis of ARPKD by Targeted Manipulation of Pkhd1$292,050
R01 · FY2004 · DK